How to Fight Insurance Denials for Men's Sexual Health Treatment: TRT and ED Therapy

Testosterone replacement therapy (TRT) and erectile dysfunction (ED) treatments are among the most frequently denied men's health therapies in the United States. Insurers commonly reject testosterone cypionate, gels, newer oral formulations like Jatenzo and Kyzatrex, PDE5 inhibitors (sildenafil, tadalafil), alprostadil injections, vacuum devices, and penile implants—often citing vague "medical necessity" language or outdated lab thresholds. This stems from legitimate concerns about overuse in bodybuilding and anti-aging clinics, but it also results in medically appropriate claims being denied for men with documented hypogonadism, post-prostatectomy ED, diabetic autonomic dysfunction, or treatment-refractory sexual dysfunction. This guide explains the most common denial templates, the specific clinical citations insurers respect, and concrete steps to overturn each denial reason.

Why Insurers Deny Men's Sexual Health Treatment

1. "Lab values do not meet policy threshold"

Many plans require total testosterone below 200–300 ng/dL on two separate morning measurements. Denials cite a single borderline value (e.g., 280 ng/dL), a non-fasting or afternoon draw, or failure to repeat. Some plans ignore free testosterone even when total testosterone is low-normal but sex hormone-binding globulin (SHBG) is elevated, which reduces bioavailable testosterone.

2. "Not documented treatment failure of first-line therapy"

For ED, most policies mandate documented trials of generic PDE5 inhibitors (sildenafil or tadalafil) at maximum tolerated doses before covering branded alternatives (Stendra/avanafil), alprostadil injections, vacuum devices, or penile implants. For TRT, some plans insist on trial of low-cost testosterone cypionate or generic gel before approving Aveed, Xyosted, oral undecanoate (Jatenzo/Tlando/Kyzatrex), or compounded pellets.

3. "Contraindication exists or safety criteria not met"

Insurers deny TRT if prostate-specific antigen (PSA) is above threshold (often >4 ng/mL, or >3 ng/mL age-adjusted), hematocrit exceeds 50–52%, history of prostate or breast cancer is documented, or severe untreated obstructive sleep apnea (OSA) is present. ED therapies are denied if nitrate use is documented (absolute contraindication to PDE5 inhibitors) or recent major cardiovascular event occurred.

4. "Investigational, cosmetic, or not medically necessary"

Plans label TRT as "anti-aging," "quality of life," or "elective" if symptoms are vague, if validated questionnaires (Aging Males' Symptoms [AMS], Androgen Deficiency in the Aging Male [ADAM], International Index of Erectile Function [IIEF-5]) are missing, or if a man is over 65 with "age-appropriate" testosterone. Penile implants and Xiaflex for Peyronie's disease are often deemed investigational or cosmetic despite FDA approval and guideline support.

5. "Formulary restriction or step therapy not completed"

Newer agents—Aveed (long-acting testosterone undecanoate injection approved March 2014 with Risk Evaluation and Mitigation Strategy [REMS]), Xyosted (subcutaneous auto-injector), Jatenzo/Tlando/Kyzatrex (oral testosterone undecanoate approved 2019–2022), Stendra (avanafil)—are routinely relegated to non-preferred tiers. Plans demand prior authorization showing intolerance, allergy, or failure of cheaper alternatives.

The Citations Insurers Respect

When you appeal, reference these specific guidelines and studies by name and year. Insurers' medical directors recognize these as authoritative.

Testosterone Replacement Therapy:

• Endocrine Society Clinical Practice Guideline: Testosterone Therapy in Men with Hypogonadism, 2018 – Defines hypogonadism as total testosterone <264 ng/dL by liquid chromatography–mass spectrometry (LC-MS/MS) on two separate morning measurements, with symptoms. This is the most cited threshold.
• American Urological Association (AUA) Guideline: Evaluation and Management of Testosterone Deficiency, 2018 – Uses a cutoff of <300 ng/dL on two occasions, emphasizes symptom assessment with validated tools (AMS, ADAM), and recognizes primary, secondary, and late-onset hypogonadism as treatable.
• FDA labels for Aveed (March 2014), Jatenzo (March 27, 2019), Tlando (March 28, 2022), Kyzatrex (July 27, 2022) – Cite the specific approval dates and indications for "hypogonadism in adult males" to counter "investigational" denials.
• Travison et al., J Clin Endocrinol Metab 2017 – Established age- and methodology-specific reference ranges; supports lower thresholds with LC-MS/MS assays.

Erectile Dysfunction:

• AUA Guideline: Evaluation and Management of Erectile Dysfunction, 2018 (amended 2023) – First-line: PDE5 inhibitors; second-line: intracavernosal alprostadil, vacuum devices; third-line: penile prosthesis. Documents that failure of maximum-dose PDE5 inhibitors (at least 6–8 doses per drug) warrants second-line therapy.
• IIEF-5 (International Index of Erectile Function – 5-item) / SHIM (Sexual Health Inventory for Men) – Validated scoring: 5–7 severe ED, 8–11 moderate ED, 12–21 mild-to-moderate ED. Score ≤21 with documented PDE5i failure supports advanced therapy.
• Montorsi et al., Eur Urol 2010; Mulhall et al., J Sex Med 2016 – Nerve-sparing radical prostatectomy patients benefit from early penile rehabilitation with PDE5 inhibitors or alprostadil; failure justifies implant.
• Xiaflex (collagenase clostridium histolyticum) FDA approval December 6, 2013 – Indicated for Peyronie's disease with palpable plaque and curvature >30°; cite to counter "investigational" or "cosmetic" denials.

Comorbidity and Safety Evidence:

• Sharma et al., Mayo Clin Proc 2016; Budoff et al., JAMA 2017 – No increased cardiovascular mortality with TRT in men with baseline hypogonadism; supports use post-PCI or stable CAD.
• Corona et al., Eur Urol 2014 – PDE5 inhibitors safe in stable cardiovascular disease, contraindicated only with nitrates or recent major adverse cardiovascular event (MACE).

How to Argue Against Each Denial Reason

Fighting "Lab values do not meet policy threshold"

Step 1: Confirm two separate morning (before 10 a.m.), fasting total testosterone measurements by LC-MS/MS (not immunoassay, which overestimates). If your values are 264–300 ng/dL, cite both the Endocrine Society 2018 (<264 ng/dL) and AUA 2018 (<300 ng/dL) cutoffs. State: "Patient meets AUA 2018 guideline threshold of <300 ng/dL on two separate AM measurements (dates, values)."

Step 2: If total testosterone is low-normal but free testosterone is low and SHBG is elevated, attach the lab report and state: "Bioavailable testosterone is reduced due to elevated SHBG (value). Endocrine Society 2018 recognizes low free testosterone with symptoms as indication for therapy regardless of total testosterone."

Step 3: Document symptoms with validated questionnaires. Include your AMS score (≥27 is moderate, ≥37 severe), ADAM score (≥3 positive answers suggests hypogonadism), and specific symptoms: decreased libido, fewer morning erections, fatigue, depressed mood, reduced exercise tolerance, loss of muscle mass. Have your partner corroborate if possible.

Step 4: Identify etiology—primary (testicular failure: Klinefelter, post-chemotherapy, post-orchiectomy), secondary (hypothalamic-pituitary: pituitary adenoma, opioid-induced, Kallmann syndrome), or late-onset/age-associated with symptoms. State: "This is secondary hypogonadism with low-normal LH (value), meeting Endocrine Society 2018 criteria for TRT."

Step 5: Attach a letter from your endocrinologist or urologist citing the 2018 guidelines by name and explaining why the insurer's threshold (often 200 ng/dL) is not evidence-based.

Fighting "Not documented treatment failure of first-line therapy"

For ED: Document that you have tried both sildenafil and tadalafil (or vardenafil) at maximum tolerated doses (sildenafil 100 mg, tadalafil 20 mg) for at least 6–8 doses each, on separate occasions, with adequate sexual stimulation. State dates, doses, and outcomes: "Sildenafil 100 mg × 8 doses over 12 weeks: partial response, IIEF-5 improved from 9 to 14 but still moderate ED (goal >21). Tadalafil 20 mg × 8 doses: similar partial response, headache limited tolerability." If you have organic ED (post-prostatectomy, diabetic neuropathy, pelvic radiation), emphasize that AUA 2018 and nerve-sparing literature (Montorsi 2010, Mulhall 2016) support early escalation to alprostadil or implant after PDE5i failure, not indefinite trials.

For TRT: If a newer, more convenient formulation is denied (Aveed, Xyosted, Jatenzo/Tlando/Kyzatrex), document why generic cypionate or gel failed or is inappropriate. Examples: "Testosterone cypionate 100 mg IM weekly × 24 weeks resulted in supraphysiologic peak (>1200 ng/dL) at day 2 and subtherapeutic trough (<300 ng/dL) at day 7, with mood swings. Xyosted's weekly subcutaneous auto-injector provides stable levels per product labeling and FDA approval March 2018." Or: "AndroGel 1.62% daily × 16 weeks: trough total T 310 ng/dL, inadequate symptom response, and transfer risk to toddler at home per FDA black-box warning. Oral testosterone undecanoate (Jatenzo, FDA approved March 27, 2019) bypasses transfer risk and provides stable twice-daily dosing."

Step 1: Obtain a letter from your prescribing physician documenting each prior therapy, dose, duration (minimum 12 weeks for TRT, 6–8 doses per PDE5i), lab results or symptom scores, and reason for failure (inadequate response, intolerance, safety concern).

Step 2: Cite the AUA ED guideline 2018: "Second-line therapies (intracavernosal injection, vacuum device) and third-line (penile prosthesis) are indicated after failure of maximum-dose PDE5 inhibitors, which has been documented."

Step 3: If the insurer demands yet another trial, ask them to cite the specific policy requirement and note that AUA 2018 does not require trials of all PDE5 inhibitors if two have failed at maximum dose.

Fighting "Contraindication exists or safety criteria not met"

Prostate cancer / elevated PSA: If denied because of "history of prostate cancer," cite Morgentaler et al., Eur Urol 2016 and AUA 2018, which state that TRT is not contraindicated in men with treated, low-risk prostate cancer (Gleason ≤6, stage T1c-T2a, PSA <10) who are on active surveillance or post-definitive therapy with undetectable PSA. If PSA is 3–4 ng/mL (age-adjusted threshold), state: "Patient has no prostate cancer diagnosis, no high-grade prostatic intraepithelial neoplasia (HGPIN) on prior biopsy (date), and PSA of (value) is within acceptable range for TRT per Endocrine Society 2018, which recommends baseline PSA and digital rectal exam, not absolute PSA cutoff."

Hematocrit >50%: If denied for hematocrit 50–52%, state: "Endocrine Society 2018 recommends monitoring hematocrit every 3–6 months and dose adjustment or phlebotomy if hematocrit >54%. Patient's hematocrit (value)% is managed with therapeutic phlebotomy per protocol. Hematocrit elevation is anticipated, manageable, and not an absolute contraindication." Attach phlebotomy records.

Untreated OSA: If denied for sleep apnea, document CPAP adherence: "Patient diagnosed with moderate OSA (baseline apnea-hypopnea index [AHI] 22), treated with CPAP nightly, current AHI 4.2 (optimal). Endocrine Society 2018 recommends treatment of OSA before or concurrent with TRT, which has been achieved."

Nitrate use (ED): If denied for "cardiovascular risk," confirm you are not taking nitrates. State: "Patient is not on nitrates. PDE5 inhibitors are contraindicated with nitrates but safe in stable CAD per AUA 2018 and Corona et al. 2014. Patient's cardiologist cleared for PDE5i use (attach letter)."

Recent MACE: If you had a myocardial infarction or stroke within 3–6 months, most policies correctly defer ED therapy. If >6 months and stable, cite Corona 2014 and attach cardiology clearance: "Patient is 14 months post-PCI, no recurrent angina, cleared by cardiologist (name) for sexual activity and PDE5 inhibitor use."

Fighting "Investigational, cosmetic, or not medically necessary"

TRT as "anti-aging": Insurers often deny TRT in men >65 with testosterone 250–350 ng/dL, calling it "age-appropriate decline." Counter: "AUA 2018 and Endocrine Society 2018 define hypogonadism by lab threshold (<300 or <264 ng/dL) and symptoms, not age. Patient meets biochemical threshold (two AM values <300 ng/dL) and has severe symptoms (AMS score 41, ADAM 8/10 positive, decreased libido, fatigue, loss of morning erections) impairing quality of life. 'Age-associated hypogonadism' is a recognized diagnosis (ICD-10 E29.1) and indication for TRT per AUA 2018."

Penile implant as "cosmetic": Insurers sometimes label prosthesis as elective. Counter: "AUA Guideline 2018 designates penile prosthesis as definitive third-line therapy for ED refractory to PDE5 inhibitors and alprostadil. Patient has severe ED (IIEF-5 score 7), failed sildenafil 100 mg × 8 doses and tadalafil 20 mg × 8 doses, failed alprostadil ICI 20 mcg × 6 doses (inadequate rigidity), and vacuum device × 8 weeks (poor adherence). Three-piece inflatable penile prosthesis (AMS 700 or Coloplast Titan) is medically necessary per AUA 2018, not cosmetic."

Xiaflex for Peyronie's as "investigational": Counter: "Collagenase clostridium histolyticum (Xiaflex) received FDA approval for Peyronie's disease on December 6, 2013. AUA Peyronie's Disease Guideline 2015 (updated 2021) lists Xiaflex as an option for men with palpable plaque, curvature >30°, and stable phase disease, which patient meets (curvature 52°, stable × 8 months, palpable dorsal plaque 2.1 cm)."

Step 1: Cite FDA approval dates and guideline statements verbatim in your appeal.

Step 2: Attach validated symptom scores (AMS, IIEF-5, partner corroboration) demonstrating impairment (not just preference).

Step 3: Emphasize sexual health as a component of overall health recognized by the WHO and incorporated into chronic disease management (e.g., ED as sentinel marker of cardiovascular disease per AUA).

Fighting "Formulary restriction or step therapy not completed"

Aveed, Xyosted, oral TU (Jatenzo/Tlando/Kyzatrex): State why the preferred agent (generic cypionate or gel) failed: "Testosterone cypionate IM produced peak/trough variability with mood swings and requires weekly injections, which patient cannot self-administer reliably (works offshore 3 weeks/month). Aveed (testosterone undecanoate IM, FDA approved March 2014) is administered in-office every 10 weeks after loading, ensuring adherence and stable levels per product labeling." Or: "Compounded testosterone pellets (Testopel) implanted every 4–6 months eliminate daily dosing, which patient failed due to work-travel schedule and missed gel applications documented by trough T <200 ng/dL at week 20."

Stendra (avanafil) vs. generic PDE5i: "Patient tried sildenafil 100 mg (headache, flushing), tadalafil 20 mg (myalgia, back pain limiting use). Avanafil (Stendra) has faster onset (15 minutes per label vs. 30–60 minutes) and lower side-effect rate per phase III trials (Goldstein et al., J Sex Med 2012). Medical necessity for formulary exception is documented."

Step 1: Obtain a prior-authorization letter from your physician documenting specific intolerance, contraindication, or failure of each formulary-preferred agent, with dates, doses, and outcomes.

Step 2: Cite the FDA approval and mechanism that differentiates the requested drug (e.g., Aveed's 10-week dosing, Jatenzo's oral bioavailability with food, Xyosted's auto-injector for self-administration).

Step 3: If the plan's pharmacy-benefit manager lists the drug in a higher tier with no exception process, cite your state's step-therapy override law (many states enacted them 2018–2023) and request an expedited review based on prior failures.

What We Do

We help patients gather the clinical documentation, lab results, prior-therapy records, and guideline citations that insurers require—then organize them into appeals that medical directors take seriously. If you've been denied testosterone replacement, a PDE5 inhibitor, alprostadil, a vacuum device, a penile implant, or Xiaflex, and you have documented low testosterone with symptoms or treatment-refractory ED, we can build your case with the specific Endocrine Society 2018, AUA 2018, and FDA references that overturn these denials. We don't guarantee outcomes, but we do guarantee that your appeal will be complete, cited, and written in the language insurance medical reviewers understand.

Sources

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.

2. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423–432.

3. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633–641. (Amended 2023.)

4. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161–1173.

5. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and Evaluation of an Abridged, 5-Item Version of the International Index of Erectile Function (IIEF-5) as a Diagnostic Tool for Erectile Dysfunction. Int J Impot Res. 1999;11(6):319–326.

6. Morgentaler A, Zitzmann M, Traish AM, et al. Fundamental Concepts Regarding Testosterone Deficiency and Treatment: International Expert Consensus Resolutions. Mayo Clin Proc. 2016;91(7):881–896.

7. Morgentaler A, Benesh JA, Denes BS, Kan-Dobrosky N, Harb D, Miller MG. Factors Influencing Prostate-Specific Antigen Response Among Men Treated with Testosterone Therapy for 6 Months. J Sex Med. 2014;11(11):2818–2825.

8. Sharma R, Oni OA, Gupta K, et al. Normalization of Testosterone Level Is Associated with Reduced Incidence of Myocardial Infarction and Mortality in Men. Eur Heart J. 2015;36(40):2706–2715.

9. Corona G, Rastrelli G, Isidori AM, Pivonello R, Bettocchi C, Reisman Y, Sforza A, Maggi M. Cardiovascular Risk Associated with Testosterone-Boosting Medications: A Systematic Review and Meta-Analysis. Expert Opin Drug Saf. 2014;13(10):1327–1351.

10. Montorsi F, Brock G, Lee J, et al. Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical Prostatectomy. Eur Urol. 2008;54(4):924–931.

11. Mulhall JP, Burnett AL, Wang R, et al. A Phase 3, Placebo Controlled Study of the Safety and Efficacy of Avanafil for the Treatment of Erectile Dysfunction after Nerve Sparing Radical Prostatectomy. J Urol. 2013;189(6):2229–2236.

12. Gelbard M, Lipshultz LI, Tursi J, et al. Phase 2b Study of Clinical Efficacy and Safety of Collagenase Clostridium Histolyticum in Patients with Peyronie Disease. J Urol. 2012;187(6):2268–2274.

13. U.S. Food and Drug Administration. Aveed (testosterone undecanoate) injection REMS. Approved March 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022219s000lbl.pdf

14. U.S. Food and Drug Administration. Jatenzo (testosterone undecanoate) capsules. Approved March 27, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212009s000lbl.pdf

15. U.S. Food and Drug Administration. Xiaflex (collagenase clostridium histolyticum) for Peyronie's disease. Approved December 6, 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125338s000lbl.pdf